Dechra Pharmaceuticals Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals: Major
  • ISIN: GB0009633180
GBP
38.66
0.02 (0.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Dechra Pharmaceuticals Plc stock-summary
stock-summary
Dechra Pharmaceuticals Plc
Pharmaceuticals: Major
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.
Company Coordinates stock-summary
Company Details
Lostock Gralam , NORTHWICH None : CW9 7UA
stock-summary
Tel: 44 1606 814730
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 544 Foreign Institutions (50.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Tony Rice
Non-Executive Chairman of the Board
Mr. Ian Page
Chief Executive Officer, Executive Director
Mr. Paul Sandland
Chief Financial Officer, Executive Director
Mr. Anthony Griffin
Managing Director - Dechra Veterinary Products Europe, Executive Director
Ms. Lisa Bright
Independent Non-Executive Director
Mr. Julian Heslop
Independent Non-Executive Director
Dr. Lawson Macartney
Independent Non-Executive Director
Ms. Ishbel Macpherson
Senior Independent Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

GBP 4,404 Million ()

stock-summary
P/E

59.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

32.32%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

9.81%

stock-summary
Price to Book

5.83